Are Some Cancer Drugs Costing Too Much for Too Little?

OncoTherapy Network

  Newer cancer drugs are being approved on the basis of shorter studies and on outcomes that might not predict living longer or feeling better, according to a new article published in JAMA Internal Medicine.

JAMA November 29, 2016

Research Letter

Health Care Policy and Law

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints (partial view)